 SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc., ALX Oncology Nasdaq: ALXO, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in four upcoming investor conferences. 